How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $139 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases.

Companies worth $10 billion or more are generally described as "large-cap stocks," and VRTX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. VRTX derives its primary competitive strength from its global monopoly in CF treatments, anchored by flagship blockbusters like Trikafta/Katori which generate robust cash flow to fuel its high-impact clinical pipeline.

Dear GameStop Stock Fans, Mark Your Calendars for September 8

SMCI vs. CoreWeave: 1 AI Infrastructure Model Has the Bigger Opportunity

Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here

Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today!

Despite its notable strength, VRTX slipped 1.4% from its 52-week high of $555.69, achieved on Aug. 25. Over the past three months, VRTX stock gained 30.1%, underperforming the VanEck Biotech ETF's (BBH) 32% gains during the same time frame.

Shares of VRTX rose 21.9% on a YTD basis and climbed 37.9% over the past 52 weeks, underperforming BBH's YTD 26.8% gains and 44.3% returns over the last year.